Last week we had 10 IPOs, with an average return of 16%. Caesars (NASDAQ:CZR) was a big contributor — it soared 58.20%. But there were six other deals that saw double-digit returns as well:
This week there are only three IPOs planned. Let’s take a look at each:
Ceres (NASDAQ:CERE). The company sells seeds to produce renewable bioenergy feedstocks, which helps reduce reliance on petroleum fuels.
But Ceres’ products are still in the early stages, and sales were only $6.6 million last year, with a net loss of $36.3 million.
The lead underwriter on the deal is Goldman Sachs (NYSE:GS). Ceres plans to issue 5 million shares at a price range of $16 to $17 each, which is down from the prior range of $21 to $23 (indicating soft demand for the transaction).
Brightcove (NASDAQ:BCOV). The company develops a cloud-based platform that allows companies to distribute and manage videos as well as mobile apps.
From 2008 to 2011, revenues jumped from $24.5 million to $63.6 million. But there was a loss of $17.3 million last year.
The company plans to sell 5 million shares at a price range of $10 to $12. The lead underwriter is Morgan Stanley (NYSE:MS).
TVAX Biomedical (NASDAQ:TVAX). This biotech focuses on the development of targeted cell-based treatments for cancer. This involves the use of a cancer cell vaccination and the activation of killer T cells.
After the public offering, the company plans to run a Phase III clinical trial.
TVAX plans to sell 2 million shares at a range of $9 to $11. The lead underwriter is Roth Capital.
Tom Taulli runs the InvestorPlace blog IPO Playbook, a site dedicated to the hottest news and rumors about initial public offerings. He also is the author of “The Complete M&A Handbook”, “All About Short Selling” and “All About Commodities.” Follow him on Twitter at @ttaulli or reach him via email. As of this writing, he did not own a position in any of the aforementioned securities.